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Abstract 
 
Chronic antigenic stimulation leads to T cell exhaustion, which drastically dampens T 
cell effector functions. Upon exhaustion, T cells progressively lose their proliferative capacity, 
cytokine production, and cytotoxic effector functions against tumors. T cell exhaustion 
involves programmed cell death-1 (PD-1), which is an inhibitory co-stimulation receptor. 
Limited scope of studies has been done regarding impact of PD-1 expression on the effector 
functions of γδ T cells. In this study, we investigated expression of PD-1 and its impact on 
effector functions of human γδ T cells. When γδ T cells were stimulated with phosphoantigens 
(HMBPP and POM2-C-HMBP) and analyzed using flow cytometry, PD-1 expression peaked 
on day 5 and showed gradual decline thereafter. Treatment of γδ T cells with IL-2 without 
phosphoantigen stimulation can induce steady and continuous increase in PD-1 expression 
throughout the course of experiment. These results suggest that PD-1 may be expressed on 
highly primed γδ T cells. Upon concurrent dose response and time course experiments over 5-
day period, we found that 10 µM POM2-C-HMBP treatment induced the maximum PD-1 
expression on day 5. To demonstrate effect of anti-PD-1 monoclonal antibody on effector 
function of γδ T cells against tumor cells (K562), we quantified γδ T cells’ IFN-γ release by 
using ELISA and measured the absorbance. Contrary to our initial hypothesis, addition of anti-
PD-1 monoclonal antibody did not appear to improve the effector function of γδ T cells, as 
difference in IFN-γ release among different treatment groups was not statistically significant. 
However, we found that increase in concentration of phosphoantigens increased effector 
functions of γδ T cells as demonstrated through increasing IFN-γ release. 
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Introduction 
 
Detection of and response to antigens is a central function of the immune system. T 
cells are key to these processes – their T cell receptors directly interact with antigens and/or 
their accessory molecules, and subsequent T cell receptor signaling initiates an immune 
response to the antigen. There are two types of T cell receptor dimers encoded in the human 
genome, the αβ (alpha beta) and the γδ (gamma delta) T cell receptors. αβ T cells are recognized 
as the predominant circulating lymphocytes, whereas γδ (Vγ9Vδ2) T cells compose a minor 
fraction of circulating lymphocytes found in human peripheral blood. Unlike αβ T cells that 
contribute to adaptive immune response via antigen-specific effector functions and memory 
phases, γδ T cells feature combined roles in the immune system [1]. γδ T cells participate in 
tumor surveillance and bridge two core features of the immune system – conventional innate 
and adaptive immune responses – with their unique T-cell repertoire. 
Recognition of antigens by γδ T cells is TCR-dependent but HLA-independent; 
antigen detection through γδ T cell receptors is not restricted to antigenic peptides that are 
complexed to HLA [2]. This allows interplay of γδ T cells between innate and adaptive immune 
response and broadens effector functions of γδ T cells in tumor surveillance. HLA-independent 
antigen recognition is represented by a specific subset of γδ T cell receptors including Vγ9Vδ2, 
which is the most prominent subset of γδ T cells human adults. As a pattern recognition 
receptor, Vγ9Vδ2 TCR allows Vγ9Vδ2 T cells to participate in innate-like immune response; 
Vγ9Vδ2 TCR facilitates recognition of diphosphate antigens derived from various pathogenic 
microbes, parasites, and tumors through detection of ‘molecular patterns’ inherent in them. The 
most potent γδ T cell activators include hydroxymethylbutenyl diphosphate (HMBPP) and 
isopentenyl diphosphate (IPP), which are intermediates of cellular isoprenoid biosynthesis [3-
4].  
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Accumulation of IPP is detected in dysregulated self-cells and certain tumors, as they 
may upregulate the mevalonate biosynthetic pathway. Accumulation of intracellular IPP in the 
tumors enables recognition by and activation of γδ T cells [5-6]. Upon activation, γδ T cells 
mount wide arrays of effector functions. They can lyse infected or transformed cells through 
release of cytotoxic perforin and granzymes and activate death-inducing receptor pathways, 
such as FAS and TNF-related apoptosis-inducing ligand receptors [7-8]. Therefore, in addition 
to mediating innate arm of immune response, γδ T cells are primed for their roles in adaptive 
arm of immunity. γδ T cells are highly effective at killing tumor cells and protecting the host 
via IFN-γ. IFN-γ inhibits angiogenesis and promotes HLA-1 expression by tumor cells, which 
subsequently enhances CD8+ effector cell responses against tumor [9]. Various interactions 
between γδ T cells and other effector T cells that mediate innate and adaptive immune 
responses carry significant therapeutic implications in utilizing γδ T cells in cancer 
immunotherapy. 
One of the drawbacks that underlie cancer immunotherapies includes concept of T cell 
exhaustion. Exhausted T cells refer to dysfunctional T cells upon chronic antigen stimulation 
that are not able to further mount effector immune response. Upon exhaustion, T cells 
progressively lose their proliferative capacity, cytokine production, and subsequently, 
cytotoxic functions against tumors. T cell exhaustion involves expression of costimulatory 
markers, or ‘immune checkpoints’, such as PD-1 and BTLA. The elevated expression of 
immune checkpoints on T cells from cancer patients is often considered markers of exhausted 
T cells, which cannot mount effective anti-tumor activities [10]. 
It is particularly important to understand that effector functions of γδ T cells are vastly 
affected by immune checkpoints, as checkpoint blockades are gaining heavy clinical use in 
anticancer immunotherapy. Immune checkpoints refer to series of inhibitory pathways wired 
to T cell responses as part of baseline homeostatic mechanism to maintain peripheral self-
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tolerance. Under normal physiological conditions, checkpoints are critical in preventing over-
activation of immune system and in protecting subsequent tissue damaging [11]. However, 
tumors up-regulate immune checkpoint protein ligands as means of immune escape, which 
gives rise to poorly immunogenic tumor that can readily progress. PD-1 and BTLA are two 
prominent checkpoint receptor proteins upregulated in γδ T cells following γδ T cell activation 
[12]. 
Programmed cell death-1 (PD-1) and its interaction with PDL-1/2 delivers inhibitory 
signal to TCR signal transduction, which under normal physiology would lead to 
phosphorylation of ZAP70. PDL-1/2 is often expressed on the surface of tumor cells, as they 
utilize suppressive signals mediated by various checkpoints as one of survival mechanisms. 
Phosphorylation of ZAP70 leads to downstream signal cascade that promotes T cell 
proliferation and cytokine release. Once phosphorylation of ZAP70 is halted upon PD-1 and 
PDL-1/2 interaction, downstream events that lead to T cell effector functions are subsequently 
inhibited [13]. PD-1 expression on Vγ9Vδ2 T cells increases in the presence of 
phosphoantigens and under subverted local tumor microenvironment. Furthermore, it is known 
that PD-1 activation upon its interaction with ligand PD-L1/2 attenuates effector functions of 
Vγ9Vδ2 T cells against infectious diseases and tumor [14-15]. However, when PD-1 mediated 
suppression of TCR signal cascade is blocked by using anti-PD-1 monoclonal antibodies, 
effector functions of highly primed γδ T cells are enhanced [16]. Therefore, blocking 
suppressive checkpoint signals by using monoclonal antibodies reverses γδ T cell anergy and 
exhaustion in tumor environment and promotes continuous survival and proliferation of γδ T 
cells; by facilitating γδ T cell tumor infiltration and anti-tumor cytokine productions (i.e., IFN-
γ), anti-PD-1 monoclonal antibodies targeting γδ T cells will increase chance of tumor rejection 
and host protection. 
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Along with PD-1, B and T lymphocyte attenuator (BTLA) is checkpoint receptor 
protein expressed on γδ T cells that interacts with herpesvirus entry mediator (HVEM). HVEM 
is often expressed on surface of various tumor cells. BTLA plays important role in limiting T 
cell activation to maintain baseline homeostasis and promotes maintenance of dendritic cells 
and memory T cells [17]. Upon activation, BTLA signal inhibits release of IL-17 and TNF by 
specific subset of γδ T cells. And the susceptibility of γδ T cells to inhibitory signaling of 
BTLA implies therapeutic utilization of monoclonal antibodies targeting BTLA to 
competitively inhibit BTLA-HVEM interaction [18]. 
Use of monoclonal antibodies targeting checkpoint inhibitor proteins has 
accomplished considerable success in treating solid tumors and hematological malignancies. 
As a marker of highly activated or exhausted T cells, PD-1 has been shown to result in anti-
tumor responses in patients with renal cell carcinoma, melanoma, colorectal cancer, and non-
small-cell lung cancer [19-20]. Monoclonal antibodies targeting BTLA+ CD8+ effector T cells 
has resulted in positive clinical response, suggesting that functional differences may exist 
between BTLA+ and BTLA- T cells, which ultimately result in differential anti-cancer 
therapeutic potency in patients [21]. 
Despite the fact that γδ T cells bridge innate and adaptive immune responses that can 
possibly broaden cancer therapeutic approach, the majority of checkpoint blockade studies 
have been exclusively focused on αβ T cells. Furthermore, current literature suggests that 
Vγ9Vδ2 T cell cancer immunotherapies demonstrate critical drawback in rapid exhaustion. As 
previously mentioned, Vγ9Vδ2 T cell exhaustion within the tumor microenvironment will 
attenuate Vγ9Vδ2 T cell’s proliferative and effector capacities. However, Vγ9Vδ2 T cell 
exhaustion can be reversed upon inhibition of suppressive signals mediated by various 
checkpoint receptor proteins and their interaction with ligands [22]. Therefore, it is important 
to characterize checkpoints that suppress and attenuate highly functional effector Vγ9Vδ2 T 
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cells. Understanding of the impact of immune checkpoint interactions on Vγ9Vδ2 T cell 
signaling and effector functions will contribute to broadened understanding of essential factors 
that are required for long term survival, proliferation, and sustained activation of Vγ9Vδ2 T 
cells. This understanding will aid in resolving current drawbacks related to Vγ9Vδ2 T cells in 
the context of immunotherapies and further suggest implication of Vγ9Vδ2 T cells as 
promising therapeutic agents in treating cancer. 
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Materials/Methods 
 
Vγ9Vδ2 T Cell Culture 
 
 Human peripheral blood mononuclear cells (hPBMCs) were isolated from blood that 
was obtained from Research Blood Components (Boston, MA). Cells were frozen in freezing 
media (10% DMSO, 20% fetal bovine serum [FBS], 70% RPMI media) in liquid nitrogen 
until needed for experiments. hPBMCs were re-suspended in fresh T cell media (RPMI-1640, 
10% heat-inactivated FBS, 1x4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 
pyruvate, nonessential amino acids, β-mercaptoethanol [BME]) [23]. Cells were added to 12-
well plates according to respective conditions (control, HMBPP, and POM2-C-HMBP). Cells 
were stimulated with phosphoantigens hydroxymethylbutenyl diphosphate (HMBPP) or 
POM2-C-HMBP for 3 days and washed. 15 µL of human IL-2 (5 ng/mL) was supplemented 
every 3 days. Cells were cultured for another 10 days after phosphoantigen was washed for 
flow cytometry analysis. Experiments were performed using cells from at least 3 different 
donors. 
 
POM2-C-HMBP compound 
 
 POM2-C-HMBP (Figure 1) was synthesized by Dr. David F Wiemer at the 
University of Iowa and provided to us. 
 
Figure 1. Chemical structures of HMBPP and POM2-C-HMBP used in this study. The 
pKa of each acidic hydrogen atom (as determined by Marvin software) is given in italics 
[24]. Vγ9Vδ2 T cells detect phosphoantigens. Certain malignant tumors and infected cells 
contain express high levels of HMBPP or IPP, which will activate Vγ9Vδ2 T cells to mount 
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immune responses. HMBPP is a compound considered to be the most potent naturally Vγ9Vδ2 
T cells activator. 
 
Vγ9Vδ2 T Dose Response 
 
 Cells were cultured the same way throughout the experiments. 0.1 µM, 1 µM, and 10 
µM of HMBPP and POM2-C-HMBP were prepared and used to treat hPBMC donors. 15 µL 
of human IL-2 (5 ng/mL) was supplemented every 3 days. Phosphoantigens were washed 3 
days after initial stimulation, and cells were cultured for additional 3 days for subsequent 
flow cytometry analysis. Experiments were performed using cells from at least 3 different 
donors. 
 
Vγ9Vδ2 T Cell Flow Cytometry 
 
 Time course flow cytometry was performed on day 0-5, 7, 9, and 12 using 10 nM 
phosphoantigen concentration and on day 0-5 for dose-response experiment. Each sample 
was washed and resuspended in 200 µL of fluorescence-activated cell sorting buffer (2% 
BSA in PBS). Gamma delta T cell receptor (TCR) was labeled using FITC-anti-human pan 
gamma delta TCR monoclonal antibody (Thermo Fisher Scientific, Rockford, IL, 5A6.E9) 
Cells were co-stained with APC-anti-human CD279/PD-1 (BioLegend, San Diego, CA, 
EH12.2H7). Samples were washed twice and fixed in 16% paraformaldehyde before flow 
cytometry analysis. 
 
Vγ9Vδ2 T Dose Response and Time Course 
 
 Cells were cultured the same way throughout the experiments, and 0.1 µM, 1 µM, 
and 10 µM of HMBPP and POM2-C-HMBP were prepared and used to treat hPBMC donors. 
15 µL of human IL-2 (5 ng/mL) was supplemented every 3 days. Phosphoantigens were 
washed 3 days after initial stimulation for all conditions, and cells were stained for 
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subsequent flow cytometry analysis from day 1 to day 5, according to different conditions. 
Experiments were performed using cells from at least 3 different donors. 
 
Vγ9Vδ2 T Cell Negative Selection and K562 Pre-loading 
 
hPBMCs were stimulated with 10 µM of HMBPP and were treated with IL-2. Cells 
were expanded until day 5, as day 5 was found to be the day of maximum PD-1 expression 
from the previous dose response experiment. Phosphoantigens were washed on day 3 for 3 
times, and hPBMCs were resuspended in T cell media with IL-2 treatment. 
 In order to ensure that we examine the effector function of Vγ9Vδ2 T cells among 
hPBMCs, we used negative selection method to purify Vγ9Vδ2 T cells. Negative selection 
allows isolation of Vγ9Vδ2 T cells by magnetically labeling non-Vγ9Vδ2 T cells and 
retaining them on a MACS Column, while purified T cells pass through the column. During 
K562 pre-load and incubation period, T cell negative selection was done by using Miltenyi 
Biotec Human TCRγ/δ+ Cell Isolation Kit. 
Final concentration of 200,000 K562 cells/mL was counted and used for pre-loading 
K562 target cells. K562 cells were re-suspended in 200 µL of T cell media and were treated 
with 0.1 µM, 1 µM, and 10 µM of HMBPP and POM2-C-HMBP in 1mL tube according to 
conditions. K562 cells pre-loaded with phosphoantigens were incubated at 37 degrees for 2 
hours, washed 3 times afterwards, and re-suspended in 200 µL of T cell media. Experiments 
were performed using cells from at least 3 different donors. 
 
Vγ9Vδ2 T Cell and K562 Co-incubation and IFN-γ ELISA 
 
A Final concentration of 200,000 cells/mL for pre-loaded K562 cells and 100,000 
cells/mL for purified T cells were counted and mixed in a 96 well plate for ELISA. 20 µL of 
pre-loaded K562 cells and 120 µL of T cells were mixed for co-incubation, and LEAF 
Purified anti-human PD-1 monoclonal antibody (BioLegend, San Diego, CA, EH12.2H7) 
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was added to the desired wells. Wells were brought up to final volume of 200 µL with T cell 
media and incubated for 24 hours at 37 degrees. Supernatant on 96-well plate was used for 
ELISA experiment using BioLegend Human IFN-γ ELISA Max Deluxe Set, and ELISA was 
performed as duplicate. Experiments were performed using cells from at least 3 different 
donors. 
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Results 
 
Stimulation of PBMCs with phosphoantigens increases populations of Vγ9Vδ2 T cells  
 
 We first wanted to confirm that phosphoantigens expand Vγ9Vδ2 T cell population 
over time, so we stimulated hPBMCs with 100 nM of HMBPP and analyzed % of γδ TCR 
expression using flow cytometry (Figure 1). hPBMCs were stimulated with 100 nM of 
HMBPP for 3 days, and cells were treated with IL-2 every 3 days for total of 12 days. 
Subsequently, cells were stained with γδ TCR and were analyzed by flow cytometry from 
day 1 to day 12. Upon stimulation with 100 nM HMBPP, Vγ9Vδ2 T cell population 
gradually increased until day 12 (55.1%) compared to day 1 (10.97%). 
 
Stimulation of Vγ9Vδ2 T cells with phosphoantigens increases PD-1 expression 
 
 After determining that the phosphoantigens expanded Vγ9Vδ2 T cell population, the 
next goal was to examine effect of the phosphoantigen stimulation on Vγ9Vδ2 T cell PD-1 
expression. To investigate this, we stimulated hPBMCs with 100 nM of HMBPP and POM2-
C-HMBP for 3 days with addition of IL-2 every 3 days (Figure 2-3). Negative control 
Vγ9Vδ2 T cells were only treated with IL-2 without phosphoantigen stimulation (Figure 4). 
Cells were co-stained with antibodies towards the γδ TCR and/or PD-1 and were analyzed by 
flow cytometry from day 0 to day 12. Upon stimulation, 14% of POM2-C-HMBP and 
HMBPP treated Vγ9Vδ2 T cells expressed PD-1 as early as day 1 (24 hours after 
stimulation), and 15% of unstimulated control expressed PD-1 on day 1. PD-1 expression 
peaked on day 5 in both POM2-C-HMBP and HMBPP treated Vγ9Vδ2 T cells (23% and 
30%, respectively), and the level of PD-1 expression gradually declined thereafter, as 
proportion of Vγ9Vδ2 T cells increased; nevertheless, PD-1 expression on unstimulated 
Vγ9Vδ2 control continued to increase until day 12 without showing decline, as 37% of 
unstimulated Vγ9Vδ2 T cells expressed PD-1 on day 12 compared to 16% on day 1. 
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Stimulation of Vγ9Vδ2 T cells with 10 µM of POM2-C-HMBP for 5 days induces 
maximum PD-1 expression 
 
 Previous time course experiment demonstrated that PD-1 expression peaks on day 5 
with phosphoantigen treatments. Prior to investigating the effect of anti-PD-1 monoclonal 
antibodies on the effector function of Vγ9Vδ2 T cells, our goal was to determine the optimal 
phosphoantigen concentration that induces maximum Vγ9Vδ2 T cell PD-1 expression. To 
examine this, we concurrently performed dose response and time course experiments over 5-
day period (Figure 5).  
We stimulated hPBMCs with 0.1 µM, 1 µM, and 10 µM of HMBPP and POM2-C-
HMBP for 3 days with addition of IL-2 every 3 days. Negative control Vγ9Vδ2 T cells were 
only treated with IL-2 without phosphoantigen stimulation. Cells were co-stained with 
antibodies towards the γδ TCR and/or PD-1 and were analyzed by flow cytometry from day 1 
to day 5. As expected, maximum PD-1 expression was seen on day 5 in all conditions except 
condition treated with 0.1 µM HMBPP (23.3%). Maximum PD-1 expression was seen in 
condition treated with 10 µM POM2-C-HMBP, as 41.55% of 10 µM POM2-C-HMBP treated 
cells expressed PD-1 at day 5. As noted in previous dose response experiment, PD-1 
expression on unstimulated Vγ9Vδ2 control continued to increase and peaked on day 5, as 
19.3% of unstimulated Vγ9Vδ2 T cells expressed PD-1 on day 5 compared to 6.675% of 
unstimulated Vγ9Vδ2 T cells on day 1. 
 
Higher concentration of phosphoantigens increase release of IFN-γ from Vγ9Vδ2 T cells 
upon co-incubation with K562, while addition of PD-1 mAb decreases release of IFN-γ.  
 
 Previous research conducted by Koca showed that K562 blasts are multipotential, 
hematopoietic malignant cells that spontaneously differentiate into progenitors of the 
erythrocyte, granulocyte, and monocytic series [25]. DM Benson performed flow cytometry 
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and verified that K562 cells express PD-L1, which would down-regulate effector functions of 
T cells in tumor microenvironment [26].  
Once we determined that maximum PD-1 expression was seen on day 5 and that 10 
µM POM2-C-HMBP induced the highest expression among other treatments, we next wanted 
to determine the effect of anti-PD-1 monoclonal antibody on effector function of Vγ9Vδ2 T 
cells against tumor cells (K562). To examine this, we quantified Vγ9Vδ2 T cells’ IFN-γ 
release by using ELISA. PBMCs were stimulated for 3 days with phosphoantigens and on 
day 5 were purified using T-cell negative selection. Purified T cells were subsequently co-
incubated with K562 cells that express PD-L1/2. Release of IFN-γ and K562 expression of 
PD-L1/2 were determined by ELISA and flow cytometry, respectively (Figure 6).  
We observed that Vγ9Vδ2 T cells treated with higher concentration of 
phosphoantigen led to higher absorbance reading, as cells released higher amount of IFN-γ. 
In negative control samples where cells were only treated with IL-2 and anti-PD-1 
monoclonal antibodies, mean absorbance reading was 108, 113, 100, and 125 for cells treated 
with HMBPP, HMBPP and anti-PD-1, POM2-C-HMBP, and POM2-C-HMBP and anti-PD-1, 
respectively. Compared to negative control, at 10 µM concentration, mean absorbance 
readings were 298, 271, 252, and 274 for cells treated with HMBPP, HMBPP and anti-PD-1, 
POM2-C-HMBP, and POM2-C-HMBP and anti-PD-1, respectively.  
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Discussion 
 
PD-1 expression peaks in Vγ9Vδ2 T cells on day 5 following stimulation with 
phosphoantigens  
 
 Although the function of checkpoint inhibitors and PD-1 in αβ T cells has been 
extensively studied, little is known about roles of PD-1 in Vγ9Vδ2 T cells and their possible 
impacts on therapeutic utilization. A previous study demonstrated that human Vγ9Vδ2 T 
cells expressed PD-1 upon stimulation with phosphoantigens (HMBPP) with maximum 
expression on day 3, and gradual decline thereafter [14].  
In this study, we found that HMBPP and POM2-C-HMBP stimulations at 
subsequently lower concentration compared to previously used concentration (10 µM) [14] 
can induce Vγ9Vδ2 T cells to express PD-1, which reached maximum levels within 5 days. 
PD-1 expression showed steady decline thereafter. We also revealed that treatment of 
Vγ9Vδ2 T cells with IL-2 alone can cause Vγ9Vδ2 T cells to express PD-1 with steady 
increase until day 12 without decline in expression. Vγ9Vδ2 T cells require IL-2 for clonal 
expansion, and IL-2 treatment was continued throughout the course of experiment. Therefore, 
it is possible that PD-1 was continuously expressed on highly primed Vγ9Vδ2 T cells without 
decline, as a cellular mechanism to avoid over-activation of Vγ9Vδ2 T cells, in which it 
would lead to potential auto-immunity in physiologic function. 
 
There does not appear to be difference between HMBPP and POM2-C-HMBP in terms 
of maximum effect on PD-1 expression 
 
We conducted the flow cytometry to determine percentage of PD-1 expression in 
Vγ9Vδ2 T cells using two different types of phosphoantigens, HMBPP and POM2-C-HMBP, 
at the same concentration of 100 nM (Figure 2-3). On day 12, 17% of Vγ9Vδ2 T cells treated 
with HMBPP 100 nM expressed PD-1, and 18% of Vγ9Vδ2 T cells treated with POM2-C-
HMBP 100 nM. This could indicate that Vγ9Vδ2 T cells respond to phosphoantigens with 
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shared structural moiety in a similar way in terms of surface checkpoint protein expression. 
Possible limitation to these experiments with phosphoantigens is that the molecules share 
similar structural moiety, and we did not test multiple phosphoantigens that may prime 
Vγ9Vδ2 T cells to vastly different extent. Also, underlying mechanism by which the 
phosphoantigens induce PD-1 expression in Vγ9Vδ2 T cells is not entirely known, which  
 
There does not appear to be dose dependency in PD-1 expression on Vγ9Vδ2 T cells in 
time course experiment  
 
We conducted concurrent dose response and time course experiment to determine 
percentage of PD-1 expression in Vγ9Vδ2 at different concentrations of HMBPP over the 
course of 5 days. Although result from ELISA experiment showed statistically significant 
dose dependency in IFN-γ release, PD-1 expression did not differ significantly among 
different treatments. There is a limitation in the design of our study, as the doses that we 
chose for this experiment might not have been in the right range to observed a clear dose 
response effect. Future experiment with doses of each compound on the lower range may 
clarify the relationship between dose of phosphoantigens and PD-1 expression in Vγ9Vδ2 T 
cells. 
 
Blocking PD-1 with anti-PD-1 monoclonal antibody does not appear to increase IFN-γ 
production by Vγ9Vδ2 T cells 
 
IFN-γ release was more closely related to the concentrations of treatment rather than 
to the addition of PD-1 antibodies, as IFN-γ release increased and peaked with 1 µM of 
HMBPP (304.33) and POM2-C-HMBP (216). Our initial hypothesis was that adding anti-PD-
1 monoclonal antibody would increase IFN-γ release by counteracting the known role of 
checkpoint protein PD-1. However, it is difficult to determine why the effector function 
slightly decreased with the addition of anti-PD-1 monoclonal antibody, although difference 
was not statistically significant. 
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A major limitation to this experiment is that our experimental model may not 
perfectly represent tumor microenvironment, in which immune effector cells’ anti-tumor 
functions are downregulated largely due to complex tumor-derived signals [27]. There are 
multiple signaling pathways involved in down-regulation of anti-tumor functions of these 
immune effector cells, and our negative selection purification method may have eliminated 
potentially significant immune cell interactions that could affect PD-1 and PD-L1/2 activities 
among human PBMCs. Another limitation could be that the experiment was done using 3 
different donors, which may show variability in response to treatments with phosphoantigens 
and anti-PD-1 monoclonal antibody. 
 
Future directions and significance 
 
 Through the methods and experiments described so far, we have been able to 
confirm that both HMBPP and POM2-C-HMBP induce PD-1 expression in Vγ9Vδ2 T cells. 
There does not seem to be dose-dependency in PD-1 expression, as there was no statistically 
significant difference in percentage of PD-1 expression induced by both types of 
phosphoantigens. However, higher concentration of phosphoantigens led to higher release of 
IFN-γ from Vγ9Vδ2 T cells, as indicated by an ELISA experiment. This indicates that PD-1is 
expressed in activated Vγ9Vδ2 T cells primed by structurally similar types of 
phosphoantigens, and effector function of Vγ9Vδ2 T cells depends on the activation. We 
have investigated the potential synergistic effect of anti-PD-1 monoclonal antibodies on the 
effector function of Vγ9Vδ2 T cells, but so far have been unsuccessful in determining its 
clear role. In fact, results indicated decrease in IFN-γ release from Vγ9Vδ2 T cells treated 
with anti-PD-1 monoclonal antibody, but differences are not statistically significant. Recent 
study done by Zumwalde demonstrated that Vγ9Vδ2 T cells transferred from human PBMCs 
exhibit potent antitumor effector functions even in the absence of checkpoint inhibitor 
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treatment [28], which might suggest different roles of PD-1 in Vγ9Vδ2 T cells compared to 
those in αβ T cells and thus warrants further investigation in exact roles and mechanisms of 
PD-1 in Vγ9Vδ2 T cells.  
Further investigation into the exact roles and mechanism of PD-1 in Vγ9Vδ2 T cells 
may help to identify different pathways that should be utilized for Vγ9Vδ2 T cells as 
potential adjuvant or immunotherapeutic agent. Once we can identify the exact role and 
mechanism by which PD-1 plays in Vγ9Vδ2 T cells and clarify the difference in roles of PD-
1 in different types of T cells, we can try to utilize Vγ9Vδ2 T cells by targeting unique 
mechanisms by which PD-1 works in Vγ9Vδ2 T cells. Future studies into tumor cell lines 
that extensively express PD-L1/2 and are resistant to current immunotherapeutic agents may 
also be beneficial for development of future therapeutic modalities. For example, checkpoint 
inhibitors have been extensively utilized in the field of oncology, yet there have not been 
studies done to examine specific types of tumors that are resistant to immunotherapy and the 
mechanisms they escape the targeted therapeutic agents. Therefore, the research conducted 
thus far is the beginning of work that could enhance novel immunotherapeutics for oncology, 
and potentially other auto-immune disorders as well. 
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Figures 
 
 
Figure 1. Expression of the γδ TCR following 100 nM HMBPP stimulation. PBMCs were 
stimulated for 3 days with 100 nM HMBPP. The percentage of cells expressing the γδ TCR 
was determined by flow cytometry. Bars represent mean values and error bars represent 
standard deviations of three independent experiments. *p < 0.05 by one way ANOVA. Bars 
are compared to the different days (column).
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Figure 1-A. Expression of the γδ TCR following 100 nM HMBPP stimulation on day 1. 
PBMCs were stimulated for 3 days with 100 nM HMBPP. Cells were stained with γδ TCR on 
days 1-7, 9, and 12 and were analyzed by flow cytometry from day 1 to day 12. Panel on the 
right indicates that 10.4% of T cells out of entire donor 11 PBMCs expressed γδ TCR on day 
1 following 100 nM HMBPP stimulation.
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Figure 1-B. Expression of the γδ TCR following 100 nM HMBPP stimulation on day 5. 
PBMCs were stimulated for 3 days with 100 nM HMBPP. Cells were stained with γδ TCR on 
days 1-7, 9, and 12 and were analyzed by flow cytometry from day 1 to day 12. Panel on the 
right indicates that 6.94% of T cells out of entire donor 11 PBMCs expressed γδ TCR on day 
5 following 100 nM HMBPP stimulation.
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Figure 1-C. Expression of the γδ TCR following 100 nM HMBPP stimulation on day 7. 
PBMCs were stimulated for 3 days with 100 nM HMBPP. Cells were stained with γδ TCR on 
days 1-7, 9, and 12 and were analyzed by flow cytometry from day 1 to day 12. Panel on the 
right indicates that 12.9% of T cells out of entire donor 11 PBMCs expressed γδ TCR on day 
7 following 100 nM HMBPP stimulation.
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Figure 1-D. Expression of the γδ TCR following 100 nM HMBPP stimulation on day 12.  
PBMCs were stimulated for 3 days with 100 nM HMBPP. Cells were stained with γδ TCR on 
days 1-7, 9, and 12 and were analyzed by flow cytometry from day 1 to day 12. Panel on the 
right indicates that 39.4% of T cells out of entire donor 11 PBMCs expressed γδ TCR on day 
12 following 100 nM HMBPP stimulation. 
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Figure 1-E. Expression of the γδ TCR following 100 nM HMBPP stimulation on day 1. 
PBMCs were stimulated for 3 days with 100 nM HMBPP. Cells were stained with γδ TCR on 
days 1-7, 9, and 12 and were analyzed by flow cytometry from day 1 to day 12. Panel on the 
right indicates that 13.9% of T cells out of entire donor 12 PBMCs expressed γδ TCR on day 
1 following 100 nM HMBPP stimulation.
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Figure 1-F. Expression of the γδ TCR following 100 nM HMBPP stimulation on day 5.  
PBMCs were stimulated for 3 days with 100 nM HMBPP. Cells were stained with γδ TCR on 
days 1-7, 9, and 12 and were analyzed by flow cytometry from day 1 to day 12. Panel on the 
right indicates that 20.1% of T cells out of entire donor 12 PBMCs expressed γδ TCR on day 
5 following 100 nM HMBPP stimulation.
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Figure 1-G. Expression of the γδ TCR following 100 nM HMBPP stimulation on day 7. 
PBMCs were stimulated for 3 days with 100 nM HMBPP. Cells were stained with γδ TCR on 
days 1-7, 9, and 12 and were analyzed by flow cytometry from day 1 to day 12. Panel on the 
right indicates that 58.0% of T cells out of entire donor 12 PBMCs expressed γδ TCR on day 
7 following 100 nM HMBPP stimulation.
  
Choi 27 
 
 
Figure 1-H. Expression of the γδ TCR following 100 nM HMBPP stimulation on day 12. 
PBMCs were stimulated for 3 days with 100 nM HMBPP. Cells were stained with γδ TCR on 
days 1-7, 9, and 12 and were analyzed by flow cytometry from day 1 to day 12. Panel on the 
right indicates that 66.7% of T cells out of entire donor 12 PBMCs expressed γδ TCR on day 
12 following 100 nM HMBPP stimulation. 
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Figure 2. Expression of the γδ TCR and PD-1 following 100 nM HMBPP stimulation. 
PBMCs were stimulated for 3 days with 100 nM HMBPP. The percentage of cells expressing 
the γδ TCR and PD-1 was determined by flow cytometry over 12 days. Bars represent mean 
values and error bars represent standard deviations of three independent experiments. *p < 0.05 
by one way ANOVA. 
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Figure 3. Expression of the γδ TCR and PD-1 following 100 nM POM2-C-HMBP (054) 
stimulation. PBMCs were stimulated for 3 days with 100 nM POM2-C-HMBP (054). The 
percentage of cells expressing the γδ TCR and PD-1 was determined by flow cytometry over 
12 days. Bars represent mean values and error bars represent standard deviations of three 
independent experiments. *p < 0.05 by one way ANOVA. 
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Figure 4. Expression of the γδ TCR and PD-1 in unstimulated PBMCs. Control PBMCs 
were left unstimulated throughout the entire course of experiment. The percentage of cells 
expressing the γδ TCR and PD-1 was determined by flow cytometry over 12 days. Bars 
represent mean values and error bars represent standard deviations of three independent 
experiments. *p < 0.05 by one way ANOVA. 
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Figure 5. Dose response of γδ TCR and PD-1 expression. PBMCs were stimulated for 3 
days with 0.1 µM, 1 µM, and 10 µM of HMBPP and POM2-C-HMBP (054) for respective 
conditions. The percentage of cells expressing the γδ TCR and PD-1 was determined by flow 
cytometry over 5 days. Bars represent mean values and error bars represent standard deviations 
of three independent experiments. *p < 0.05 by one way ANOVA. Bars are compared to the 
different concentrations (row).
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Figure 6. Secretion of IFN-γ following addition of PD-1 blocking monoclonal antibody. 
PBMCs were stimulated for 3 days with phosphoantigens and on day 5 were co-incubated with 
K562 cells that express PD-L1/2. Release of IFN-γ and K562 expression of PD-L1/2 were 
determined by ELISA and flow cytometry, respectively. *p < 0.05 by one way ANOVA. Bars 
are compared to the different concentrations (row).
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